BETAMETHASONE DIPROPIONATE ointment, augmented

Land: USA

Sprog: engelsk

Kilde: NLM (National Library of Medicine)

Aktiv bestanddel:

BETAMETHASONE DIPROPIONATE (UNII: 826Y60901U) (BETAMETHASONE - UNII:9842X06Q6M)

Tilgængelig fra:

Lupin Pharmaceuticals, Inc.

Indgivelsesvej:

TOPICAL

Recept type:

PRESCRIPTION DRUG

Terapeutiske indikationer:

Betamethasone dipropionate ointment USP (augmented) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. Betamethasone dipropionate ointment (augmented) is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation. Risk Summary There are no available data on betamethasone dipropionate ointment (augmented) use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. Advise pregnant women that betamethasone dipropionate ointment (augmented) may increase the risk of having a low birthweight infant and to use betamethasone dipropionate ointment (augmented) on

Produkt oversigt:

Betamethasone dipropionate ointment USP (augmented), 0.05% is a white to off-white opaque ointment supplied in 15-g (NDC 68180-947-01) and 50-g (NDC 68180-947-02) tubes. Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Autorisation status:

Abbreviated New Drug Application

Produktets egenskaber

BETAMETHASONE DIPROPIONATE- BETAMETHASONE DIPROPIONATE OINTMENT,
AUGMENTED
LUPIN PHARMACEUTICALS, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
BETAMETHASONE DIPROPIONATE
OINTMENT USP (AUGMENTED) SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR BETAMETHASONE
DIPROPIONATE OINTMENT USP (AUGMENTED).
BETAMETHASONE DIPROPIONATE OINTMENT USP (AUGMENTED), FOR TOPICAL USE
INITIAL U.S. APPROVAL: 1983
RECENT MAJOR CHANGES
Warnings and Precautions,
Ophthalmic Adverse Reactions (5.2) 05/2019
INDICATIONS AND USAGE
Betamethasone dipropionate ointment USP (augmented) is a
corticosteroid indicated for the relief of the inflammatory and
pruritic manifestations of corticosteroid-responsive dermatoses in
patients 13 years of age and older. (1)
DOSAGE AND ADMINISTRATION
• Apply a thin film to the affected skin areas once or twice daily.
(2)
• Discontinue therapy when control is achieved. (2)
• Limit therapy to no more than 2 consecutive weeks. (2)
• Use no more than 50 g per week. (2)
• Do not use with occlusive dressings unless directed by a
physician. (2)
• Avoid use on the face, groin, or axillae, or if skin atrophy is
present at the treatment site. (2)
• Not for oral, ophthalmic, or intravaginal use. (2)
DOSAGE FORMS AND STRENGTHS
• Ointment, 0.05% (3)
CONTRAINDICATIONS
• Hypersensitivity to any component of this medicine. (4)
WARNINGS AND PRECAUTIONS
Effects on endocrine system: Betamethasone dipropionate ointment
(augmented) can cause reversible HPA axis
suppression with the potential for glucocorticosteroid insufficiency
during and after withdrawal of treatment. Risk
factor(s) include the use of high-potency topical corticosteroids, use
over a large surface area or to areas under
occlusion, prolonged use, altered skin barrier, liver failure, and use
in pediatric patients. Modify use should HPA axis
suppression develop. (5.1, 8.4)
Opthalmic Adverse Reactions: Betamethasone dipropionate ointment
(augmented) may increase the r